Active Prostate Cancer Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Prostate Cancer Clinical Trial?

• Find Trials That Fit — Browse recruiting Prostate Cancer trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Prostate Cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Prostate Cancer Clinical Trial FAQ

Are there clinical trials for castration-resistant prostate cancer (CRPC)?

Yes, CRPC is one of the most active areas of prostate cancer research. Trials are testing next-generation androgen receptor inhibitors, PARP inhibitors (especially for BRCA1/2 or HRR gene mutations), lutetium-177 PSMA therapy (radioligand), and novel immunotherapy combinations. Many of these are available for both non-metastatic and metastatic CRPC.

Do I need genetic (BRCA) testing before joining a prostate cancer trial?

Not always, but BRCA1/2 and other homologous recombination repair (HRR) gene mutations now qualify patients for PARP inhibitor trials (olaparib, rucaparib, niraparib). Germline and somatic testing is increasingly recommended for metastatic prostate cancer, so ask your urologist or oncologist if you haven't been tested.

Can patients receiving hormone therapy (ADT) join prostate cancer trials?

Many trials require patients to be on or have previously received androgen deprivation therapy (ADT). The specific eligibility depends on whether the trial targets hormone-sensitive or castration-resistant disease. Trialify's eligibility questionnaire will ask about your current and prior hormone therapy to help narrow down the most relevant trials.

What is a PSMA scan, and do I need one for a prostate cancer trial?

A PSMA PET scan uses a radioactive tracer to identify prostate cancer cells that express the PSMA protein. Several trials — including lutetium-177 PSMA and PSMA-targeted therapies — require a positive PSMA PET scan for enrollment. If your cancer center offers PSMA imaging, ask your oncologist if it's appropriate for your situation.

How does Trialify help prostate cancer patients find a trial?

You enter your disease stage, prior treatments, and location. Trialify searches ClinicalTrials.gov for recruiting studies that match your profile and rewrites the complex eligibility criteria into plain yes-or-no questions. You get a match assessment and a printable summary ready for your next oncology appointment — with no account or personal data required.

Explore Other Cancer Trial Guides

• Metastatic Prostate Cancer — Metastatic prostate cancer includes hormone-sensitive (mHSPC) and castration-resistant (mCRPC) stages. Trials are advancing PARP inhibitors (for HRR gene mutations), lutetium-177 PSMA radioligand therapy, novel AR inhibitors, and immunotherapy strategies across all metastatic disease settings.
• Bladder Cancer — Bladder cancer trials are evaluating checkpoint immunotherapy, enfortumab vedotin-based combinations, and FGFR inhibitors for both non-muscle-invasive and muscle-invasive disease.
• Kidney Cancer — Kidney cancer trials are evaluating immunotherapy combinations, HIF-2α inhibitors like belzutifan, and novel TKI regimens for clear cell and non-clear cell renal cell carcinoma.
• Colorectal Cancer — Colorectal cancer trials are evaluating immunotherapy for MSI-H tumors, KRAS and BRAF targeted therapies, and novel combinations for metastatic disease. Many trials enroll both colon and rectal cancer patients.